We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+29.88%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
+$38.4M
Cap. Flow
+$19.7M
Cap. Flow %
11.56%
Top 10 Hldgs %
54.57%
Holding
80
New
11
Increased
19
Reduced
14
Closed
12

Top Buys

Rank Stock Value
1
LRCX icon
Lam Research
LRCX
+$6.27M
2
NTLA icon
Intellia Therapeutics
NTLA
+$3.52M
3
CMPX icon
Compass Therapeutics
CMPX
+$3.32M
4
BCYC
Bicycle Therapeutics
BCYC
+$2.28M
5
SLDB icon
Solid Biosciences
SLDB
+$2.22M

Top Sells

Rank Stock Value
1
AXGN icon
Axogen
AXGN
+$2.12M
2
INBX icon
Inhibrx
INBX
+$1.91M
3
QURE icon
uniQure
QURE
+$1.85M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$1.16M
5
PRTA icon
Prothena Corp
PRTA
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.96%
2 Technology 19.61%
3 Energy 3.55%
4 Materials 0.54%
5 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
76
Karyopharm Therapeutics
KPTI
$149M
– –
-27,985
Closed -$183K
SRRK icon
77
Scholar Rock
SRRK
$6.27B
– –
-26,000
Closed -$968K
TELA icon
78
TELA Bio
TELA
$31.6M
– –
-155,000
Closed -$231K
XLV icon
79
State Street Health Care Select Sector SPDR ETF
XLV
$41.4B
– –
-1,498
Closed -$208K
ZBIO
80
Zenas BioPharma
ZBIO
$1.96B
– –
-16,500
Closed -$366K
1 2 3
4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Birchview Capital held 80 positions worth $171M, up 29% from $132M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital deployed $19.7M of net new capital in Q4 2025, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Lam Research: 40,329 shares worth $6.9M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Inhibrx, an estimated $1.91M trimmed.

  • Birchview Capital's largest Q4 2025 buy was Lam Research: 40,329 shares worth $6.9M.
  • Birchview Capital added most to Intellia Therapeutics in Q4 2025, an estimated $3.52M increase.
  • Birchview Capital's biggest Q4 2025 reduction was Inhibrx, cutting an estimated $1.91M.
  • Birchview Capital fully exited Axogen in Q4 2025, selling an estimated $2.12M.
  • Birchview Capital's ten largest holdings make up 55% of its $171M portfolio in Q4 2025.
  • Birchview Capital opened 11 new positions and closed 12 in Q4 2025.
  • Birchview Capital's portfolio value rose 29% quarter-over-quarter to $171M.

Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.